Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

BEAM Dec 20 '24 40.00 Call

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [N/A]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ rootItem.symbol ]]underlying price [[ rootItem.lastPrice ]] [[ rootItem.priceChange ]] ([[ rootItem.percentChange ]]) [[ rootItem.tradeTime ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
Image of Cathie Wood via Wikimedia Commons
Cathie Wood Just Bet $26 Million on Broadcom Stock. Should You Buy AVGO Too? Barchart - Fri Jan 30, 11:33AM CST

Cathie Wood bets on Broadcom while shorting major market names in a week of activity.

BLSH : 31.88 (-0.53%)
ARKX : 31.28 (-2.16%)
NFLX : 79.62 (-3.15%)
META : 668.69 (-0.30%)
ROKU : 87.89 (-3.32%)
TXG : 19.15 (unch)
GTLB : 30.02 (-4.85%)
AVGO : 342.76 (+0.68%)
TWST : 49.64 (+1.18%)
ILMN : 116.38 (-2.46%)
CRCL : 57.86 (-3.16%)
WRD : 7.55 (-5.74%)
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition GlobeNewswire - Sun Jan 11, 4:00PM CST

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application...

BEAM : 25.99 (-3.56%)
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Thu Dec 18, 2025

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 25.99 (-3.56%)
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting GlobeNewswire - Sat Dec 6, 2025

Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to

BEAM : 25.99 (-3.56%)
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference GlobeNewswire - Wed Nov 12, 2025

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 25.99 (-3.56%)
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire - Tue Nov 4, 2025

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026...

BEAM : 25.99 (-3.56%)
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting GlobeNewswire - Mon Nov 3, 2025

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 25.99 (-3.56%)
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM) Tipranks - Sat Oct 11, 2025

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics today and set a price target of $80.00. The company’s shares closed yesterday at $27.87.Elevate Your Investing Strategy:...

BEAM : 25.99 (-3.56%)
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences GlobeNewswire - Mon Aug 25, 2025

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 25.99 (-3.56%)
More news for this symbol

BEAM Related stocks

Symbol Latest 3M %Chg
BEAM 25.99 +15.61%
Beam Therapeutics Inc
AZN 204.76 +14.92%
Astrazeneca Plc
AMGN 366.58 +8.31%
Amgen Inc
GILD 155.80 +27.12%
Gilead Sciences Inc
BMY 59.93 +23.01%
Bristol-Myers Squibb Company
GSK 58.49 +20.82%
Gsk Plc ADR

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot